No Data
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
VIVA BIOTECH (01873.HK) spent 0.228 million HKD to repurchase 0.2625 million shares on December 23.
Gelonghui, December 23 – VIVA BIOTECH (01873.HK) announced that on December 23, it spent 0.228 million HKD to repurchase 0.2625 million shares.
VIVA BIOTECH (01873.HK) spent 0.681 million HKD to repurchase 0.794 million shares on December 17.
Gelonghui reported on December 17 that VIVA BIOTECH (01873.HK) announced that on December 17, it spent 0.681 million Hong Kong dollars to repurchase 0.794 million shares.
VIVA BIOTECH (01873.HK) spent 0.919 million HKD to repurchase 1.05 million shares on December 16.
Gelonghui, December 16 - VIVA BIOTECH (01873.HK) announced that on December 16, it spent 0.919 million Hong Kong dollars to repurchase 1.05 million shares.
VIVA BIOTECH (01873.HK) spent 0.448 million HKD to repurchase 0.5 million shares on December 13.
Gelonghui, December 13丨VIVA BIOTECH (01873.HK) announced that on December 13, HKD 0.448 million was spent to repurchase 0.5 million shares.
VIVA BIOTECH (01873.HK) spent 0.093 million Hong Kong dollars to repurchase 0.1 million shares on December 11.
Gelonghui, December 11th丨VIVA BIOTECH (01873.HK) announced that on December 11th, it spent 0.093 million Hong Kong dollars to repurchase 0.1 million shares.
No Data
